electroCore to Join Russell Microcap® Index
2024年6月11日 - 9:00PM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
medicine and wellness company, announced today that its stock is on
the preliminary additions list for inclusion in the Russell
Microcap
® Index after its 2024 annual
reconstitution. The newly reconstituted indexes will take effect
after the market close on June 28, 2024, with the newly effective
reconstituted family of indices beginning trading after the open of
trading on July 1, 2024, according to a preliminary list of
additions posted by FTSE Russell on May 24, 2024.
“We are pleased to have been selected to join the
Russell Microcap® Index,” said Brian Posner, Chief
Financial Officer of electroCore. “Inclusion in the index may
increase our exposure to the investment community.”
The Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $10.5 trillion in
assets are benchmarked against the Russell’s US indexes. The
Russell indexes are part of FTSE Russell, a leading global index
provider.
For more information on the Russell Microcap®
Index and the Russell indexes reconstitution, go to the “Russell
Reconstitution” section on the FTSE Russell website.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine
and wellness company dedicated to improving health and promoting
general wellness through its non-invasive vagus nerve stimulation
(“nVNS”) technology platform. The company’s is focused on the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general wellbeing and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release and other written and oral statements made by
representatives of electroCore may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include, but
are not limited to, statements about electroCore's business
prospects, the impact of electroCore’s inclusion in the Russell
Microcap® Index , new and existing wellness product offerings, new
ecommerce site, and clinical and product development plans; its
pipeline or potential markets for its technologies; the timing,
outcome and impact of regulatory, clinical and commercial
developments including focus group study results; the Company’s
business prospects in the United States (including its e-commerce
initiatives) and other new markets and other statements that are
not historical in nature, particularly those that utilize
terminology such as "anticipates," "will," "expects," "believes,"
"intends," other words of similar meaning, derivations of such
words and the use of future dates. Actual results could differ from
those projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the ability to raise
the additional funding needed to continue to pursue electroCore’s
business and product development plans, the inherent uncertainties
associated with developing new products or technologies, the
ability to commercialize gammaCore™, the ability to successfully
launch and commercialize Truvaga Plus, the potential impact and
effects of COVID-19 on the business of electroCore, electroCore’s
results of operations and financial performance, and any measures
electroCore has and may take in response to COVID-19 and any
expectations electroCore may have with respect thereto, competition
in the industry in which electroCore operates and overall market
conditions. Any forward-looking statements are made as of the date
of this press release, and electroCore assumes no obligation to
update the forward-looking statements or to update the reasons why
actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents electroCore files with the SEC available at
www.sec.gov.
Contact:ECOR Investor Relations(973)
302-9253investors@electrocore.com
electroCore (NASDAQ:ECOR)
過去 株価チャート
から 5 2024 まで 6 2024
electroCore (NASDAQ:ECOR)
過去 株価チャート
から 6 2023 まで 6 2024